Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Replicel Life Sciences Inc (TSV: RP ) N/A UNCHANGED Last Price Updated: 3:56 PM EDT, Mar 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Replicel Life Sciences Inc < Previous 1 2 Next > RealPage Announces Strategic Partnership with Habitat for Humanity International to Build Housing in Local Communities December 14, 2023 From RealPage, Inc. Via Business Wire RealPage Accelerates the Pace of Innovation for Multifamily with Market-Leading AI-Enabled Front Office Suite November 15, 2023 From RealPage, Inc. Via Business Wire RealPage Unveils New Multifamily Rental Trends August 08, 2023 From RealPage Via Business Wire RepliCel Provides Corporate Update November 28, 2022 Via ACCESSWIRE RepliCel Announces Material Patent Milestones in Key Markets August 04, 2022 Via ACCESSWIRE RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence March 28, 2023 From RealPage Via Business Wire Key Cannabis Exec Changes You Need To Know About: Curaleaf Names Director Of Social Equity & More Industry Appointments December 09, 2022 Curaleaf Names Director Of Social Equity Via Benzinga Grabbing Opportunity In Texas Migration Numbers, Rental Fund Buys Dallas-Area Single-Family Home Development August 18, 2022 A joint venture between two Fundrise-sponsored funds has led to the acquisition of 18 rental homes in the Ridgeview Villas community in Allen, Texas, north of Dallas. Via Benzinga DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections August 02, 2022 Via ACCESSWIRE RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release... From RepliCel Life Sciences, Inc. Via AccessWire Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Material Patent Milestones January 10, 2022 New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc.... From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property RepliCel Closed Final Tranche of Strategic Investment Commitment December 21, 2021 VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Terminates License Agreement with Shiseido December 21, 2021 VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... From RepliCel Life Sciences, Inc. Via AccessWire RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry December 07, 2021 From RealPage, Inc. Via Business Wire RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing November 11, 2021 Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team November 09, 2021 RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc.... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line October 28, 2021 Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Dermal Injector Update October 27, 2021 Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE /... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021 After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021 Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC /... From RepliCel Life Sciences, Inc. Via AccessWire Topics Economy Exposures Economy RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021 - Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy... From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property RealPage To Acquire G5, Leader in Real Estate Marketing Optimization July 20, 2021 From RealPage, Inc. Via Business Wire RealPage Announces New Prepaid Debit Card Solution July 13, 2021 From RealPage, Inc. Via Business Wire RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies July 07, 2021 Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /... From RepliCel Life Sciences, Inc. Via AccessWire RealPage Launches Revolutionary Water Management Solution: Smart Water July 06, 2021 From RealPage, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.